News

“Basically, your skin sees sunlight and freaks out a bit – it can get itchy, bumpy, red, rashy [and] sometimes even hive-like ...
PP, formerly known as Besnier's prurigo gestationis and early pregnancy prurigo, begins around the 25th to 30th weeks of gestation as pruritic and erythematous papules and nodules in the extensor ...
Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year treatment period, according to long-term extension data presented at the ...
Exciting times are ahead in the next few years for the prurigo nodularis treatment market as it is projected to grow to $2.11 billion in 2029, marking a compound annual growth rate CAGR of 5.1%.
Original results from the phase 3 OLYMPIA 1 (NCT04501679) and 2 (NCT04501666) trials demonstrated the safety and efficacy of nemolizumab administered subcutaneously every 4 weeks in 560 patients ...
The global report for nodular prurigo market is predicted to reveal substantial growth from 2024 to 2025, showing a market worth of $1.17 billion expanding to $1.25 billion.
ZUG, Switzerland, June 18, 2025--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe ...
Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5 (4):e42. doi: 10.1097/itx.0000000000000042 ...
Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...
This randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the safety and efficacy of povorcitinib (INCB54707) in adult patients with prurigo nodularis (PN ...